Andere Sprachen Glaukos Corporation

Aktien

A14VCK

US3773221029

GKOS

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 26.04.2024			% 5 Tage	% 1. Jan.
99,48 ^USD	-0,63 %		+3,09 %	+25,15 %

11.04.	GLAUKOS CORPORATION : Mizuho Securities bekräftigt seine neutrale Bewertung	ZM
11.04.	Glaukos-Insider verkaufte Aktien im Wert von $6.008.359, laut einer aktuellen SEC-Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Glaukos Announces the Release of its 2023 Sustainability Report	16.04.
Glaukos Insider Sold Shares Worth $6,008,359, According to a Recent SEC Filing	11.04.
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1	10.04.
Sector Update: Health Care Stocks Rise Wednesday Afternoon	03.04.
Glaukos Says iDose TR Assigned Permanent J-Code From US Centers for Medicare and Medicaid Services	03.04.
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)	03.04.
Glaukos Corporation Receives Permanent J-Code for iDose TR (travoprost intracameral implant)	03.04.
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting	01.04.
Translational Vision Science and Technology Journal Publishes RadiusXR's NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry	26.03.
Glaukos Insider Sold Shares Worth $1,153,557, According to a Recent SEC Filing	08.03.
Celanese Announces Commercial Launch of Glaukos' iDose TR (Travoprost Intracameral Implant) using Celanese's VitalDose Ethylene Vinyl Acetate (EVA)	01.03.
Glaukos Insider Sold Shares Worth $736,000, According to a Recent SEC Filing	29.02.
Glaukos Insider Sold Shares Worth $423,487, According to a Recent SEC Filing	27.02.
Glaukos : Q4 2023 Earnings Transcript	22.02.
Glaukos Q4 Non-GAAP Loss Widens, Sales Increase	21.02.
Earnings Flash (GKOS) GLAUKOS CORPORATION Reports Q4 Revenue $82.4M, vs. Street Est of $78.5M	21.02.
Glaukos: Q4 Earnings Snapshot	21.02.
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results	21.02.
Glaukos Corporation Reaffirms Financial Guidance for 2024	21.02.
Glaukos Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Glaukos Corporation

Aktien

A14VCK

US3773221029

GKOS

Andere Sprachen

Filter